Disclosure of Value Transfers

Methodological Note

Country	United Kingdom
Entity Name	Mylan UK Healthcare Limited
Legal Basis for Disclosure	Medicines for Europe Code of Conduct on Interactions with the Healthcare Community, published February 2015 Updated in January 2016
Reporting Period	2019
Currency of	All values are disclosed in
disclosed values	□ EUR
	□ Pound sterling
Value identification an d Recognition	All values disclosed are based on value transfers actually made within the respective category. Such value transfers have been made to a specific recipient as booked in the respective reporting period.
Multi-Year Contracts	Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period.
Data disclosed for	All values are disclosed for
	□ Recipients which have been engaged by entity
	☑ Recipients which have their residence in the country
VAT and other taxes	All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction
Disclosure location:	[Link to company website or other disclosure location]
Value category: "Meetings, educational support and site	The company discloses value transfers in this category as per Option 2 of the Medicine for Europe Transparency Requirements: Aggregate total amount of support provided to Healthcare
visits of HCPs"	Professionals per individual conference or meeting as follows:

Annex Document No.: Version:

Date of Publication:

Date:

Page:

Disclosure of Value Transfers

	Sponsorship for attending a third party organised congress (as
	per section 4.4):
	- name of congress,
	- aggregated amount spent for the congress, including the
	- number of Healthcare Professionals financially supported to
	attend
	• Site visits (as per section 4.5): aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
	• Company organised meeting: aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
Other Remarks	For value categories related to HCPs, aggregate values have been disclosed for 2019 following the advice provided by Medicines for Europe.
	Fees paid in connection with research & development activities or market research have not been disclosed.

https://saas2-emea-ags.compltech.iqvia.com/aggregatespend360/

Annex Document No.: Version: Date of Publication:

00

Date:

Page: